Study Reveals Compliance Delays Impact Drug Batch Releases in Pharma Plants

Delays in releasing drug batches at pharmaceutical manufacturing facilities are increasingly linked to ongoing investigations into production incidents, according to a recent survey conducted by Vector Consulting Group. The study highlights that unresolved compliance issues are causing significant disruptions in operational efficiency, with some investigations extending up to six months.

The research, titled The Compliance Spiral in Pharma Manufacturing, gathered insights from 30 professionals working in mid-to-large scale US Food and Drug Administration (USFDA)-approved formulation plants based in India. While the exact number of plants represented in the survey was not specified, the findings paint a clear picture of widespread challenges in handling manufacturing incidents.

Every plant surveyed reported having pending investigations, with 90 percent indicating they had between 15 and 35 open cases at any given time. This backlog is demanding a considerable amount of senior management’s attention, with an estimated 27 percent of their time devoted to managing these unresolved issues. This focus on incident management detracts from efforts to enhance productivity and improve production yields.

The study identified human error as the leading cause of production incidents, accounting for 56 percent. Equipment malfunctions were the second most common factor at 23 percent, followed by procedural shortcomings responsible for 11 percent of incidents. These findings underline the multifaceted nature of challenges in pharmaceutical manufacturing environments.

Documentation burdens and supervisory workload emerged as critical factors contributing to recurring errors. Operators reportedly made an average of 120 entries per batch production record alongside their standard manufacturing tasks. Documentation mistakes were significant, with 93 percent of respondents stating that such errors made up at least 20 percent of production incidents.

Supervisory responsibilities also appear stretched, as 80 percent of participants said supervisors managed five or more production lines per shift. This heavy oversight load limits the supervisors’ ability to thoroughly verify processes and catch potential errors before they result in deviations.

"The real test of a robust quality system is not how much documentation it generates, but whether it helps prevent errors and resolve deviations without disrupting production," said Chandrachur Datta, a partner at Vector Consulting Group and co-author of the study’s white paper.

Delays in closing investigations also contribute to production setbacks. The survey revealed that 83 percent of respondents experienced multiple revisions to their investigation reports, while 77 percent linked slow evidence collection to gaps in available information. Conflicting priorities between departments were cited by 73 percent as a reason for delays or the need to redo work.

Investigation timelines varied considerably, with cases involving few revisions averaging around 29 days to close. In contrast, those with extensive revisions took approximately 48 days. This disparity indicates inefficiencies in the investigation and resolution process that impact overall manufacturing schedules.

To address these issues, the report recommends simplifying batch record documentation, reducing the supervisory workload, and fostering better collaboration between production and quality assurance teams. Vector Consulting Group estimates that implementing these changes could reduce new manufacturing incidents by 30 to 50 percent and shorten investigation closure times by 20 to 40 percent.

Pharmaceutical manufacturing faces constant pressure to maintain high quality standards while meeting production targets. Compliance and quality assurance play a vital role in safeguarding patient safety and regulatory approval. However, this study shows that excessive documentation and stretched resources may inadvertently hamper manufacturing efficiency.

As the pharmaceutical sector continues to grow and evolve, balancing compliance requirements with operational effectiveness remains a key challenge. Studies like this provide valuable insights for industry leaders seeking to optimize processes, reduce delays, and maintain product quality in a competitive environment.